A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth

Cancer Research

Volumn 73, Issue 10, 2013, Pages 3132-3144

  Lau, Ted ^a   Chan, Emily ^b   Callow, Marinella ^a   Waaler, Jo ^g   Boggs, Jason ^c   Blake, Robert A ^c   Magnuson, Steven ^d   Sambrone, Amy ^c   Schutten, Melissa ^e   Firestein, Ron ^f   Machon, Ondrej ⁱ   Korinek, Vladimir ⁱ   Choo, Edna ^c   Diaz, Dolores ^e   Merchant, Mark ^b   Polakis, Paul ^a   Holsworth, Daniel D ^h   Krauss, Stefan ^g   Costa, Mike ^a,f  

^a Departments of Cancer Targets   (United States)

^b Departments of Translational Oncology   (United States)

^c Drug Metabolism and Pharmacokinetics ^*  (United States)

^d Discovery Chemistry   (United States)

^e Safety Assessment   (United States)

^f GENENTECH INC   (United States)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h ODIN Therapeutics AS   (Norway)

ⁱ INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; BETA CATENIN; ENZYME INHIBITOR; G 007LK; G 244LM; TAMOXIFEN; TANKYRASE; UNCLASSIFIED DRUG; WNT PROTEIN;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; COLONY FORMATION; COLORECTAL CANCER; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GENE MUTATION; INTESTINE CRYPT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR SPHEROID; TUMOR SUPPRESSOR GENE;

ANIMALS; AXIN PROTEIN; BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; GENES, APC; HUMANS; MICE; MUTATION; PIPERIDINES; SPHEROIDS, CELLULAR; SULFONES; TANKYRASES; TRIAZOLES; WNT SIGNALING PATHWAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877720042     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4562     Document Type: Article

References (45)

1. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62.
2. Lum L, Clevers H. The unusual case of Porcupine. Science 2012;337:922-3.
3. Stamos JL, Weis WI. The b-catenin destruction complex. Cold Spring Harb Perspect Biol 2013;5:a007898.
4. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235-7.
5. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
6. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011;6:479-507.
7. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
8. Sato T, van Es JH, Snippert HJ, Stange DE, Vries RG, van den Born M, et al. Paneth cells constitute the niche for Lgr5 stem cells in intestinal crypts. Nature 2011;469:415-8.
9. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al. Lineage tracing reveals Lgr5+stem cell activity in mouse intestinal adenomas. Science 2012;337:730-5.
10. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, et al. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002; 111:241-50. (Pubitemid 35292444)
11. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D, et al. Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector.EMBORep 2003;4: 609-15. (Pubitemid 36939953)
12. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300. (Pubitemid 36418379)
13. Scholer-Dahirel A, Schlabach MR, Loo A, Bagdasarian L, Meyer R,Guo R, et al. Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 2011;108:17135-40.
14. Cong F, Zhang J, Pao W, Zhou P, Varmus H. A protein knockdown strategy to study the function of beta-catenin in tumorigenesis. BMC Mol Biol 2003;4:10.
15. Lee E, Salic A, Krüger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003;1:E10.
16. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20.
17. Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS ONE 2011;6:e22595.
18. Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol 2011;13:623-9.
19. Chen B, Dodge ME, Tang W, Lu J,MaZ, Fan CW, et al. Small moleculemediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
20. Karlberg T, Markova N, Johansson I, Hammarström M, Schütz P, Weigelt J, et al. Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor. J Med Chem 2010;53: 5352-5.
21. Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 2011;71:197-205.
22. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 2012;72:2822-32.
23. James RG, Davidson KC, Bosch KA, Biechele TL, Robin NC, Taylor RJ, et al. WIKI4, a novel inhibitor of tankyrase and Wnt/ß-catenin signaling. PLoS ONE 2012;7:e50457.
24. Narwal M, Venkannagari H, Lehtiö L. Structural basis of selective inhibition of human tankyrases. J Med Chem 2012;55:1360-7.
25. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O, et al. [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: Antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J Med Chem 2012;55:1127-36.
26. Pinto D, Gregorieff A, Begthel H, Clevers H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. Genes Dev 2003;17:1709-13. (Pubitemid 36870334)
27. Kuhnert F, Davis CR, Wang HT, Chu P, Lee M, Yuan J, et al. Essential requirement for Wnt signaling in proliferation of adult small intestine and colon revealed by adenoviral expression of Dickkopf-1. Proc Natl Acad Sci U S A 2004;101:266-71. (Pubitemid 38084239)
28. Gong Y, Bourhis E, Chiu C, Stawicki S, DeAlmeida VI, Liu BY, et al. Wnt isoform-specific interactions with coreceptor specify inhibition or potentiation of signaling by LRP6 antibodies. PLoS One 2010;5:e12682.
29. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459:262-5.
30. Hottiger MO, Hassa PO, Lüscher B, Schüler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci 2010;35:208-19.
31. Hoeflich KP, Merchant M, Orr C, Chan J, Den Otter D, Berry L, et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res 2012;72:210-19.
32. Chang W, Dynek JN, Smith S. TRF1 is degraded by ubiquitinmediated proteolysis after release from telomeres. Genes Dev 2003;17:1328-33. (Pubitemid 36666001)
33. Guettler S, LaRose J, Petsalaki E, Gish G, Scotter A, Pawson T, et al. Structural basis and sequence rules for substrate recognition by Tankyrase explain the basis for cherubism disease. Cell 2011;147: 1340-54.
34. Kim MK, Dudognon C, Smith S. Tankyrase 1 regulates centrosome function by controlling CPAP stability. EMBO Rep 2012;13:724-32.
35. Kodama S, Ikeda S, Asahara T, Kishida M, Kikuchi A. Axin directly interacts with plakoglobin and regulates its stability. J Biol Chem 1999;274:27682-8.
36. Yauch RL, Gould SE, Scales SJ, Tang T, Tian H, Ahn CP, et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008; 455:406-10.
37. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69:7672-80.
38. Luo F, Poulogiannis G, Ye H, Hamoudi R, Arends MJ. Synergism between K-rasVal12 and mutant Apc accelerates murine large intestinal tumourigenesis. Oncol Rep 2011;26:125-33.
39. Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, et al. Colorectal tumors are effectively eradicated by combined inhibition of beta-catenin, KRAS, and the oncogenic transcription factor ITF2. Cancer Res 2010;70:7253-63.
40. Casas-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res 2012;72:4154-64.
41. Tenbaum SP, Ordonez-Moran P, Puig I, Chicote I, Arques O, Landolfi S, et al. b-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med 2012;18:892-901.
42. Tian H, Biehs B, Warming S, Leong KG, Rangell L, Klein OD, et al. A reserve stem cell population in small intestine renders Lgr5-positive cells dispensable. Nature 2011;478:255-9.
43. Yan KS, Chia LA, Li X, Ootani A, Su J, Lee JY, et al. The intestinal stem cell markers Bmi1 and Lgr5 identify two functionally distinct populations. Proc Natl Acad Sci U S A 2012;109: 466-71.
44. Bakker ER, Hoekstra E, Franken PF, Helvensteijn W, van Deurzen CH, van Veelen W, et al. b-Catenin signaling dosage dictates tissuespecific tumor predisposition in Apc-driven cancer. Oncogene. 2012 Oct 8. [Epub ahead of print].
45. Voronkov A, Holsworth DD, Waaler J, Wilson SR, Ekblad B, Perdreau-Dahl H, et al. Structural basis and SARfor G007-LK, a lead stage 1,2,4-triazole based specific tankyrase 1/2 inhibitor. J Med Chem. 2013 Mar 11. [Epub ahead of print].